Abstracts Archive - Page 1313 of 2607 - ACR Meeting Abstracts

Abstract Number: 1900 • 2018 ACR/ARHP Annual Meeting
FGFR3/ FGF9 Regulates the Activity of Profibrotic Cytokine and Growth Factor Pathways to Drive Fibroblast Activation and Tissue Fibrosis in Systemic Sclerosis
Debomita Chakraborty¹, Lena Summa², Thuong Trinh-Minh³, Chih-Wei Chen³, Alina Soare², Andreas Ramming⁴, Oliver Distler⁵, Georg Schett² and Jörg Distler³, ¹Department of Internal Medicine 3- Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁵Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Fibroblast growth factor receptor3 (FGFR3) is a member of the family of 4 different receptors (FGFR1-4) with more than 23 identified ligands FGF1-23. Each…
Abstract Number: 1901 • 2018 ACR/ARHP Annual Meeting
Reduced SPAG17 Expression Links Dysfunctional Cilia, Morphogen Signaling Activation and Multiple Organ Fibrosis: Novel Target for Systemic Sclerosis
Paulene Sapao¹, Bo Shi², Elisha D.O. Roberson³, John Atkinson⁴, Jerome Strauss¹, Maria Teves¹ and John Varga², ¹Virginia Commonwealth University, Richmond, VA, ²Northwestern University, Chicago, IL, ³Depts. of Medicine and Genetics, Division of Rheumatology, Washington University, St. Louis, MO, ⁴Medicine/Rheumatology, Washington University School of Medicine, St. Louis, MO
Background/Purpose: Persistent myofibroblast activation driving progressive fibrosis is the defining hallmark of systemic sclerosis (SSc). Uniquely, fibrosis in SSc affects the skin, heart, lungs and…
Abstract Number: 1902 • 2018 ACR/ARHP Annual Meeting
Pathogenic and Therapeutic Modulation of Activating Epigenetic Memory at a Novel Enhancer for TGFβ2 in Systemic Sclerosis
Joseph Shin¹, Zsuzsanna McMahan², Julie J. Paik², Ami A. Shah³, Fredrick M. Wigley³ and Harry C. Dietz^1,4, ¹Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Howard Hughes Medical Institue, Bethesda, MD
Background/Purpose: Systemic Sclerosis (SSc) is an etiologically mysterious disease, in which adults acquire an inflammatory prodrome with progressive fibrosis of the skin and viscera. In…
Abstract Number: 1903 • 2018 ACR/ARHP Annual Meeting
Molecular Analysis of a Skin Equivalent Tissue Culture Model System of Systemic Sclerosis Using RNA Sequencing, Epigenetic Assays, Histology, and Immunoassays
Diana M. Toledo¹, Mengqi Huang², Yue Wang², Bhaven K. Mehta², Tammara A. Wood³, Avi Smith⁴, Yolanda Nesbeth⁵, Irena Ivanovska⁶, Brock Christensen⁷, Patricia A. Pioli⁸, Jonathan Garlick⁴ and Michael L. Whitfield⁹, ¹Department of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ³Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Tufts University School of Medicine, Boston, MA, ⁵Celdara Medical, LLC, Lebanon, NH, ⁶Celdara Medical, LLC, Hanover, NH, ⁷Geisel School of Medicine at Dartmouth, Hanover, NH, ⁸Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, ⁹Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: The molecular mechanisms of systemic sclerosis (SSc) have been difficult to study outside of patient samples. Mouse models often lack key features of the…
Abstract Number: 1904 • 2018 ACR/ARHP Annual Meeting
Orphan Nuclear Receptor Rorα Is a Key Regulator of Tgfβ- and WNT-Signaling in Fibrotic Diseases
Rosebeth Kagwiria¹, Ruifang Liang¹, Alexandru Matei¹, Niclas Sihler², Chih-Wei Chen¹, Thomas Burris³, Oliver Distler⁴, Georg Schett¹ and Jörg Distler¹, ¹Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, University Hospital Erlangen, Erlangen, Germany, ²Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany, ³Department of pharmacology and physiology, Saint Luis University-school of medicine, Florida, USA, St. Louis, Missouri, MO, ⁴Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: The Retinoic-acid related Orphan Receptor-alpha (RORα) is a member of the nuclear receptor superfamily and a ligand-dependent transcription factor implicated in a wide range…
Abstract Number: 1905 • 2018 ACR/ARHP Annual Meeting
Lower Education Level Is Associated with Higher Risk of Developing Rheumatoid Arthritis
Paola de Pablo¹, Dora Romaguera², Salvatore Panico³, Amalia Mattiello³, Diana Gavrila⁴, Carmen Navarro⁴, Carlotta Sacerdote⁵, Paolo Vineis⁶, Rosario Tumino⁷, William Ollier⁸, Elio Riboli⁶, Patrick Venables⁹ and Benjamin Fisher¹⁰, ¹University of Birmingham, Birmingham, United Kingdom, ²CIBER-OBN (Fisiopatología de la Obesidad y Nutrición), University Hospital Son Espases, Palma, Spain, ³Federico II University of Naples, Naples, Italy, ⁴Murcia Regional Health Council, Murcia, Spain, ⁵Città della Salute e della Scienza University-Hospital, Turin, Italy, ⁶Imperial College London, London, United Kingdom, ⁷"Civic - M.P.Arezzo" Hospital, Ragusa, Italy, ⁸Division of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁹Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ¹⁰Rheumatology, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Lower socio-economic status (SES) has been associated with worse clinical outcomes, reduced functional ability and lower quality of life; however, little is known about…
Abstract Number: 1906 • 2018 ACR/ARHP Annual Meeting
Abdominal Obesity and Risk of Developing Rheumatoid Arthritis in Women
Bing Lu¹, Jeffrey A. Sparks², Sara K. Tedeschi³, Susan Malspeis⁴, Karen Costenbader² and Elizabeth Karlson⁵, ¹Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ⁴Rheumatology, Immunology and Allergy, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Being overweight or obese increases the risk of rheumatoid arthritis (RA) among women, particularly among those diagnosed with RA at earlier ages. Abdominal obesity…
Abstract Number: 1907 • 2018 ACR/ARHP Annual Meeting
High Serum Adiponectin Associates with the Incidence of Rheumatoid Arthritis in Obese Subjects
Cristina Maglio¹, Yuan Zhang², Christian Herder³, Anna Rudin⁴ and Lena Carlsson⁵, ¹Dep. of Rheumatology and Inflammation Research and Wallenberg Centre for Molecular and Translational Medicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ²Dep. of Rheumatology and Inflammation Research, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ³German Diabetes Center, Düsseldorf, Germany, ⁴Dept of Rheumatology and Inflammation Research, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ⁵Department of Molecular and Clinical Medicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Adiponectin, a cytokine mainly produced by the adipose tissue, plays an important role in several metabolic and inflammatory processes. In obese subjects, serum adiponectin…
Abstract Number: 1908 • 2018 ACR/ARHP Annual Meeting
Bariatric Surgery Does Not Affect the Incidence of Rheumatoid Arthritis in Obese Subjects
Yuan Zhang¹, Cristina Maglio², Anna Rudin³ and Lena Carlsson⁴, ¹Dep. of Rheumatology and Inflammation Research, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ²Dep. of Rheumatology and Inflammation Research and Wallenberg Centre for Molecular and Translational Medicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ³Dept of Rheumatology and Inflammation Research, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ⁴Department of Molecular and Clinical Medicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Obesity is among the risk factors for rheumatoid arthritis (RA). Bariatric surgery is an effective treatment to achieve weight loss and to prevent obesity-related…
Abstract Number: 1909 • 2018 ACR/ARHP Annual Meeting
Impact and Timing of Smoking Cessation on Reducing Risk for Seropositive Rheumatoid Arthritis Among Women
Xinyi Liu¹, Cianna Leatherwood¹, Sara K. Tedeschi¹, Medha Barbhaiya², Cameron Speyer¹, Bing Lu³, Karen Costenbader¹, Elizabeth Karlson¹ and Jeffrey A. Sparks¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Compared to never smoking, past and current smoking are both associated with increased risk of seropositive rheumatoid arthritis (RA). Thus, smoking cessation may delay…
Abstract Number: 1910 • 2018 ACR/ARHP Annual Meeting
Impact of Cyclic Citrullinated Peptide Autoantibody Level on Progression to Rheumatoid Arthritis Among CCP-Positive Patients without RA in a Clinical Setting
Julia Ford¹, Xinyi Liu², Allison Marshall¹, Alessandra Zaccardelli¹, Maria Prado¹, Charlene Wiyarand³, Bing Lu⁴, Elizabeth Karlson², Peter Schur¹, Kevin D. Deane⁵ and Jeffrey A. Sparks², ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, University of Colorado Denver, Aurora, CO
Background/Purpose: Autoantibodies to cyclic citrullinated peptide (CCP) are present years prior to the onset of clinical RA. This observation was based on blood bank samples from individuals who later developed…
Abstract Number: 1911 • 2018 ACR/ARHP Annual Meeting
The Expanding Clinical Spectrum of Patients with Deficiency of Adenosine Deaminase 2 (DADA2)
Karyl Barron¹, Amanda Ombrello², Deborah Stone², Patrycja M. Hoffmann², Tina Romeo², Anne Jones³, Natalia Sampaio Moura², Oskar Schnappauf², Ivona Aksentijevich³, Jenna Bergerson¹, Ariane Soldatos⁴, Camilo Toro³, Theo Heller⁵, Jennifer Kanakry⁶, Katherine R Calvo⁷ and Daniel Kastner³, ¹National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ²NHGRI, National Institutes of Health, Bethesda, MD, ³National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁴NINDS, National Institutes of Health, Bethesda, MD, ⁵NIDDK, National Institutes of Health, Bethesda, MD, ⁶NCI, National Institutes of Health, Bethesda, MD, ⁷CC/DLM, National Institutes of Health, Bethesda, MD
Background/Purpose: The deficiency of adenosine deaminase 2 (DADA2) was initially described in 2014 in 2 reports: one emphasizing early-onset lacunar strokes, livedoid rash and intermittent…
Abstract Number: 1912 • 2018 ACR/ARHP Annual Meeting
Treatment of Cardiac Sarcoidosis: A Comparative Study of Steroids Alone Versus Steroids Associated with Immunosuppressive Drugs
Thomas Ballul¹, Raphaël Borie¹, Bruno Crestani¹, Eric Daugas¹, Vincent Descamps¹, Philippe Dieude¹, Antoine Dossier¹, Fabrice Extramiana¹, Thomas Papo¹ and Karim Sacre², ¹Université Paris-Diderot, Paris, France, ²Bichat Hospital, Paris Diderot University, Paris, France
Background/Purpose: To analyze the efficacy of steroids and immunosuppressive drugs in the prevention of relapse in cardiac sarcoidosis. Methods: In this monocentric retrospective study, all…
Abstract Number: 1913 • 2018 ACR/ARHP Annual Meeting
Management of Ventricular Tachycardia and Cardiomyopathy in the Rheumatologist World: A Retrospective Review of Diagnostic Tools and Treatment Decisions for Cardiac Sarcoidosis
Saba Ziaee¹, Siri Kunchakarra², Cara Joyce³, Mark Rabbat⁴ and Rochella A. Ostrowski⁵, ¹Loyola University Medical Center, Maywood, IL, ²Cardiology, Loyola University Medical Center, Maywood, IL, ³Clinical Research Office, Loyola University Medical Center, Maywood, IL, ⁴Division of Cardiology, Loyola University Medical Center, Maywood, IL, ⁵Division of Rheumatology, Loyola University Medical Center, Maywood, IL
Background/Purpose: Cardiac sarcoidosis has been noted in 2-7% of patients with sarcoidosis. However, the incidence is >20% based on necropsy data. Given the poor yield…
Abstract Number: 1914 • 2018 ACR/ARHP Annual Meeting
Rheumatic Syndromes Associated with Immune-Checkpoint Inhibitors: A Single-Center Cohort of 61 Patients
Michael Richter¹, Cynthia S. Crowson², Lisa Kottschade³, Heidi Finnes³, Svetomir N. Markovic⁴ and Uma Thanarajasingam⁵, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Oncology, Mayo Clinic, Rochester, MN, ⁴Department of Medicine and Oncology, Mayo Clinic, Rochester, MN, ⁵Department of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Rheumatologists are increasingly called upon to manage the autoimmune side effects of immune-checkpoint inhibitors (ICIs). However, these new entities are poorly understood and treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].